MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present...
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm...
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022...
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and...
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQSEATTLE, Oct. 11,...
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -...
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing...
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo,...
FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filingSupports...
MIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare...
Collaboration aims to accelerate drug discovery and advance company’s tRNA synthetase platformSAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr...
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily...
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical...
Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for ClientsMORRISVILLE, N.C., Oct. 11, 2022...
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE...
Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7%...
Experienced nephrologist brings extensive clinical leadership and industry expertise to drive transformational approaches to treating kidney diseasesCAMBRIDGE, Mass., Oct. 11,...